Loading stock data…
iBio (IBIO)
$1.73+0.06 (+3.59%)
After Hours$1.75+0.02 (+1.16%)· Last close Jun 29
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
iBio, Inc. in the Healthcare sector is trading at $1.73 with a market capitalization of $79M. Wall Street consensus targets $5.53 (8 analysts), implying a +219.4% move over the next 12 months. The stock is currently 55% below its 52-week high of $3.82, remaining 1.1% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +219.4% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0↓ | $100,000↓ | $200,000 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$8.37M↑ | -$9.45M↓ | -$5.95M↓ | -$5.20M↓ | -$4.88M |
| Net Income | -$7.73M↑ | -$8.99M↓ | -$5.72M↓ | -$5.16M↓ | -$4.86M |
Peer Comparison
JNJUNHPFE
Fundamentals
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides improved C...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$79.49M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-35.60%
Volume
Today's trading volume
1.12M
Recent News
Could iBio (IBIO) Be an Underrated Obesity Stock?
With 16 hedge funds having stakes in the stock, iBio, Inc. (NASDAQ:IBIO) is among the 10 Under-the-Radar AI Stocks to Buy in 2026. On June 8, Raymond James initiated coverage of iBio, Inc. (NASDAQ:IBIO) with an Outperform rating and a $5 price target, highlighting the company’s emerging obesity-focused pipeline and attractive risk-reward profile. The firm pointed to […]
We're Not Very Worried About iBio's (NASDAQ:IBIO) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, iBio...
iBio (IBIO) Receives Regulatory Clearance to Initiate Phase 1 Trial of IBIO-600
iBio Inc. (NASDAQ:IBIO) is one of the best NASDAQ growth stocks to buy and hold forever. On April 8, iBio received regulatory clearance and ethics approval to initiate its first-in-human Phase 1 clinical trial of IBIO-600 in Australia. This randomized, double-blind, placebo-controlled study will evaluate the safety, tolerability, and pharmacokinetics of the therapy in overweight […]
iBio Details Generative AI Antigen Platform to Speed GPCR Antibody Discovery and Close “Trust Gap”
iBio (NASDAQ:IBIO) is seeking to narrow what it views as a growing “trust gap” between the promise of generative AI in drug discovery and the high cost and long timelines of bringing a drug to market, according to Alex Taguchi, the company’s Director of Machine Learning. In a webinar presentation on
iBio Touts Bispecific Antibody Strategy for PH-HFpEF, Eyes Development Candidate in Q3
Executives at iBio (NASDAQ:IBIO) outlined the scientific and strategic rationale for a myostatin/activin A bispecific antibody program that the company believes could become a next-generation therapy for heart failure, with an initial focus on pulmonary hypertension associated with heart failure wit